Systemic Therapies in Docetaxel-Naïve, Biomarker-Unrestricted Metastatic Castration-Resistant Prostate Cancer (mCRPC) after Prior Androgen Receptor Pathway Inhibitor (ARPI) or Androgen Deprivation Therapy (ADT): A Systematic Literature Review (SLR) and Indirect Treatment Comparison (ITC)
Publication date: Available online 13 November 2026 Source: Clinical Genitourinary Cancer Author(s): Kyle Flannery, Kevin Steele, Paul Serafini, Gaurang Nazar, Divya Pushkarna, Mir Sohail Fazeli, Pedro Barata
Systemic Therapies in Docetaxel-Naïve, Biomarker-Unrestricted Metastatic Castration-Resistant Prostate Cancer (mCRPC) after Prior Androgen Receptor Pathway Inhibitor (ARPI) or Androgen Deprivation Therapy (ADT): A Systematic Literature Review (SLR) and Indirect Treatment Comparison (ITC). // Clinical Genitourinary Cancer. – URL: https://www.sciencedirect.com/science/article/pii/S155876732600217X?dgcid=rss_sd_all
Systemic Therapies in Docetaxel-Naïve, Biomarker-Unrestricted Metastatic Castration-Resistant Prostate Cancer (mCRPC) after Prior Androgen Receptor Pathway Inhibitor (ARPI) or Androgen Deprivation Therapy (ADT): A Systematic Literature Review (SLR) and Indirect Treatment Comparison (ITC). Clinical Genitourinary Cancer. https://www.sciencedirect.com/science/article/pii/S155876732600217X?dgcid=rss_sd_all
“Systemic Therapies in Docetaxel-Naïve, Biomarker-Unrestricted Metastatic Castration-Resistant Prostate Cancer (mCRPC) after Prior Androgen Receptor Pathway Inhibitor (ARPI) or Androgen Deprivation Therapy (ADT): A Systematic Literature Review (SLR) and Indirect Treatment Comparison (ITC).” Clinical Genitourinary Cancer.
@article{article40993,
title = {Systemic Therapies in Docetaxel-Naïve, Biomarker-Unrestricted Metastatic Castration-Resistant Prostate Cancer (mCRPC) after Prior Androgen Receptor Pathway Inhibitor (ARPI) or Androgen Deprivation Therapy (ADT): A Systematic Literature Review (SLR) and Indirect Treatment Comparison (ITC)},
journal = {Clinical Genitourinary Cancer},
url = {https://www.sciencedirect.com/science/article/pii/S155876732600217X?dgcid=rss_sd_all}
}
Objective To assess prostate‐specific antigen (PSA) testing according to income, age, and region of residence in Sweden. Patients and Methods We conducted a nationwide, population‐based open cohort study of men aged 40–90 years in...